Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has entered into a nonexclusive collaboration with Korea-based Lunit, a leading provider of AI for cancer diagnostics and therapeutics, to develop AI-based companion diagnostic solutions.

The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

They will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent's state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.

The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options.

Brandon Suh, CEO of Lunit, said, "Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation. By combining Agilent's global leadership in tissue-based diagnostics with Lunit's proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence - ultimately ensuring patients receive the right treatment at the right time."

Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division at Agilent, noted that the collaboration with Lunit further strengthens their ability to offer the most advanced companion diagnostic solutions.

"Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide,” she added.

They plan to initially focus on the co-development of AI-powered assays for use in research and clinical trials.